| 5.23 0.1 (1.95%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.76 |
1-year : | 7.89 |
| Resists | First : | 5.78 |
Second : | 6.76 |
| Pivot price | 5.07  |
|||
| Supports | First : | 5 |
Second : | 4.52 |
| MAs | MA(5) : | 4.95 |
MA(20) : | 5.16 |
| MA(100) : | 5.13 |
MA(250) : | 4.69 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 48.6 |
D(3) : | 31.6 |
| RSI | RSI(14): 51.9 |
|||
| 52-week | High : | 7.19 | Low : | 1.13 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ALDX ] has closed below upper band by 25.7%. Bollinger Bands are 38.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.29 - 5.31 | 5.31 - 5.33 |
| Low: | 4.96 - 4.98 | 4.98 - 5 |
| Close: | 5.19 - 5.22 | 5.22 - 5.26 |
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Tue, 11 Nov 2025
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London - The Globe and Mail
Mon, 10 Nov 2025
ALDX: BTIG Reiterates Buy Rating with Price Target Maintained at $9.00 | ALDX Stock News - GuruFocus
Thu, 06 Nov 2025
Aldeyra (NASDAQ: ALDX) sets R&D update webcast, pipeline review on Nov 13 at 8 a.m. ET - Stock Titan
Wed, 24 Sep 2025
After Two Regulatory Setbacks For Reproxalap, Can Aldeyra's Persistence Pay Off? - RTTNews
Sat, 23 Aug 2025
JonesTrading Lifts Aldeyra Therapeutics, Inc. (ALDX) Price Target to $9 - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 60 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 3 (%) |
| Held by Institutions | 58.2 (%) |
| Shares Short | 4,680 (K) |
| Shares Short P.Month | 5,380 (K) |
| EPS | -0.86 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.92 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -31.6 % |
| Return on Equity (ttm) | -66 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.89 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -41 (M) |
| Levered Free Cash Flow | 18 (M) |
| PE Ratio | -6.16 |
| PEG Ratio | 0 |
| Price to Book value | 5.68 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.66 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|